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Introduction
Chromosomal abnormalities occur in 0.1–0.2% of
live-born infants. The incidence of trisomy 13 live
births has been reported to range from 1/5,000 to
1/30,000 [1–8]. Trisomy 13 was first described by
Patau et al [9] in 1960 and is the third most common
trisomy following trisomies 21 and 18. Trisomy 13
represents the presence of an extra chromosome 13
resulting from a free copy or translocation. Molecular
analysis of the free extra chromosome 13 revealed
that in more than 80% of patients, it resulted from
a maternal meiotic nondisjunction [10]. Clinically,
it manifests many associated congenital anomalies
including malformations of the brain, craniofacial
defects, heart defects, limb defects, and severe
mental retardation. The complex malformations usu-
ally result in miscarriage or intrauterine fetal death
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Fetuses with trisomy 13 are characterized by many associated congenital anomalies includ-
ing defects of the brain, face, heart, and limbs. The complex anomalies usually result in
early embryo death or intrauterine fetal death in the late stages. Only 5–10% of live births
have a longer survival time after delivery but these patients are often mentally retarded.
Prenatal sonography has been reported to detect more than 90% of trisomy 13 fetuses with
major structural defects in the second trimester. In recent years, the addition of soft markers
to the sonographic screening for fetal trisomy 13 in the first trimester has been significantly
beneficial. This article provides an overview of the common sonographic features of fetal
trisomy 13 with major structural abnormalities including brain defects, midline facial defects,
cardiac anomalies, genitourinary anomalies, limb anomalies and abdominal wall defects,
and minor structural abnormalities including increased nuchal translucency thickness,
echogenic intracardiac focus, fetal tachycardia, and megacystis. Several diseases may
have phenotypic overlaps with trisomy 13 syndrome including Meckel-Gruber syndrome,
pseudotrisomy 13 syndrome, Smith-Lemli-Opitz syndrome, Pallister-Hall syndrome, and
hydrolethalus syndrome. Due to the seriousness of this congenital anomaly, increased
understanding of the different sonographic markers will improve the detection of trisomy 13
and prenatal ultrasound is a valuable tool in detecting a variety of congenital structural
malformations of this lethal syndrome throughout gestation.
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throughout the gestation [11]. Even after birth, the
majority of affected fetuses die shortly thereafter.
Only 5–10% of live births have a longer survival time
and the survivors often have mental retardation [1].
In obstetric practice, ultrasound is a valuable tool
in the detection of fetal structural anomalies, and it
has been reported to detect more than 90% of
fetuses with trisomy 13 [12,13]. Here, we review the
associated prenatal sonographic features in the detec-
tion of fetal trisomy 13. The common major sonogra-
phic abnormalities of fetal trisomy 13 include brain
defects, midline facial defects, cardiac anomalies,
genitourinary anomalies, limb anomalies, and abdo-
minal wall defects, and minor sonographic abnor-
malities include increased nuchal translucency
thickness (NT), echogenic intracardiac focus (EIF),
fetal tachycardia, and megacystis. Early prenatal
diagnosis is significantly beneficial to determina-
tion of the course of pregnancy. In addition, differen-
tial diagnoses including Meckel-Gruber syndrome,
pseudotrisomy 13 syndrome, Smith-Lemli-Opitz
syndrome, Pallister-Hall syndrome, and hydroletha-
lus syndrome are discussed. Both the prenatal sono-
graphic features and differential diagnoses of trisomy
13 are summarized in Table 1.
Prenatal Sonographic Features
Prenatal ultrasound has been extensively applied in
the assessment of fetal chromosomal aneuploidy for
a long time. Clinically, two types of sonographic mar-
kers suggestive of aneuploidy are used. Type I mark-
ers represent major fetal structural abnormalities
and type II markers, also called soft markers, are
characterized by nonspecific and often transient
fetal abnormalities.
Type I Markers — Major Structural 
Abnormalities
Currently, type I sonographic markers in the majority 
of fetuses with trisomy 13 include the anomalies of
the brain, the face, the heart, the genitourinary tract,
the limbs, and abdominal wall defects in the second
trimester. Above 14 weeks of gestation, Picklesimer
et al [14] found that all the major structural anom-
alies of trisomy 13 could be prenatally detected.
With the advent of high-quality ultrasound equip-
ment, many structural abnormalities of fetal trisomy
13 can be detected before the second trimester. In a
first trimester scanning between 11 and 13+6 weeks
of gestation, sonographic findings of holopros-
encephaly (HPE), exomphalos, and/or megacystis
can be seen in approximately 50% of trisomy 13
fetuses [15]. Clinically, most pregnant women pre-
fer early identification of the major fetal structural
defects and this service can significantly promote
their autonomy.
Brain anomalies
The brain anomalies in trisomy 13 patients include
HPE, agenesis of the corpus callosum, cerebellar
anomalies, hydrocephalus, ventriculomegaly, enlar-
ged cisterna magna, and microcephaly [13]. HPE is
a severe malformation in the brain and is caused
by impaired midline cleavage of the embryonic pro-
sencephalon resulting in different degrees of fusion
of the lateral ventricles [16]. The variable pheno-
types of HPE can be classified as alobar type, semilo-
bar type, lobar type, and a middle interhemispheric
fusion variant. Alobar HPE is characterized by total
absence of interhemispheric fissure, the third ven-
tricle, falx cerebri, neurohypophysis, and olfactory
bulbs. Semilobar HPE is characterized by partial
separation of posterior cerebral hemispheres with
presence of occipital lobe and usually the absence
of olfactory bulbs and corpus callosum. Lobar HPE is
characterized by complete division of cerebral
hemispheres with a variable degree of fusion at the
cingulated gyrus [17]. Genetic and nongenetic fac-
tors can both result in the development of fetal
HPE. In cases with HPE of an abnormal karyotype,
trisomy 13 is the most frequent, and approxi-
mately 70% of fetuses with trisomy 13 can manifest
HPE [7,18]. Prenatal diagnosis of HPE was first
described by Kurtz et al in 1980 [19]. The most
specific sonographic findings in trisomy 13 with
alobar HPE are single fused lateral ventricle, fusion
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of the thalami, and no visible midline structures in
the midtrimester. The associated findings often in-
clude the presence of a dorsal sac and midline facial
anomalies such as cyclopia, hypotelorism, anoph-
thalmia, arhinia, proboscis, and midline facial clefts
[20,21]. In a sonographic scanning of 28 trisomy
13 fetuses between 13 and 25 weeks of gestation,
brain anomalies were detected in 18 fetuses (18/28,
64.3%), of which ventriculomegaly and HPE were
the most common [22]. Recently, first-trimester
sonographic screening for fetal trisomy 13 has re-
ported that HPE can be detected as early as 9+2
weeks’ gestation with improved ultrasound equip-
ment [23]. Sepulveda et al proposed that failure to
identify the “butterfly” sign which describes visual-
ization of the choroid plexus in both lateral ventri-
cles is a warning sign of HPE in the first trimester [24].
Facial anomalies
Normally developed facial features depend on the
normal development of the underlying brain struc-
tures. Because of the common brain anomalies in
fetuses with trisomy 13, midline facial defects are
also frequently seen. The facial anomalies associated
with alobar HPE are invariably characterized by a
wide range of midline facial defects ranging from a
single incisor to cyclopia and clinically these features
can be classified as cyclopia, ethmocephaly, cebo-
cephaly, and median cleft lips [17,25,26]. The main
facial features in cyclopia include median mono-
phthalmia, synophthalmia or anophthalmia, and
absent or single proboscis. Ethmocephaly manifests
extreme hypotelorism and a proboscis above the
orbits. Cebocephaly is characterized by ocular hypo-
telorism and single nostril nose. Features in the case
Table 1. Prenatal sonographic features of trisomy 13 and differential diagnoses
Prenatal sonographic features
● Type I markers — major structural anomalies
Brain anomalies: holoprosencephaly, agenesis of the corpus callosum, cerebellar anomalies, hydrocephalus,
ventriculomegaly, enlarged cisterna magna, and microcephaly.
Facial anomalies: cyclopia, ethmocephaly, cebocephaly, median cleft lips, a single incisor, and absent or hypoplastic
nasal bone.
Cardiac anomalies: ventricular septal defects, atrial septal defects, patent ductus arteriosus, double-outlet right
ventricle, hypoplastic left ventricle, mitral or aortic atresia, pulmonary stenosis, and anomalous venous return.
Genitourinary anomalies: pyelectasis, renal cystic dysplasia, multicystic kidneys, enlarged and echogenic kidneys, 
hydronephrosis, ureteral obstruction, and duplication.
Limb anomalies: postaxial polydactyly of the hands and feet, clenched or overlapping digits, prominent calcaneus,
and rocker bottom or club feet.
Abdominal wall defects: omphalocele, bladder exstrophy.
● Type II markers — soft markers
Increased nuchal translucency thickness
Echogenic intracardiac focus
Fetal tachycardia
Megacystis
Differential diagnoses
Meckel-Gruber syndrome
Pseudotrisomy 13 syndrome 
Smith-Lemli-Opitz syndrome 
Pallister-Hall syndrome 
Hydrolethalus syndrome
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of median cleft lips also include ocular hypotelorism
and flat nose. The variable and less severe facial
malformations associated with semilobar or lobar
HPE include hypotelorism, coloboma of the iris,
unilateral or bilateral cleft lip and/or palate, micro-
phthalmia, flat nose, and other anomalies [17,25,
26]. In a prenatal detection of 28 trisomy 13 fetuses,
midline facial defects were the most common
(12/28, 42.9%) and usually associated with the
underlying brain defects (11/12, 92%) [22]. Absent
or hypoplastic nasal bone has been suggested as a
marker for identification of fetal aneuploidy in the
first and second trimesters [27–29]. It can be
detected in approximately 34–55% of fetuses with
trisomy 13 [30,31]. Because of lack of relationship
between absent nasal bone and first trimester bio-
chemical markers in trisomy 13 fetuses, it could be
expected to increase the detection of this aneu-
ploidy after incorporating the study of the charac-
teristics of the absent nasal bone into the existing
first trimester screening program [32].
Cardiac anomalies
Congenital heart defects are common in fetuses with
trisomy 13, including ventricular septal defects,
atrial septal defects, patent ductus arteriosus, double-
outlet right ventricle, hypoplastic left ventricle, mitral
or aortic atresia, pulmonary stenosis, and anom-
alous venous return [13,33]. Cardiovascular anom-
alies were prenatally detected in 15 (53.6%) out of
28 trisomy 13 fetuses, of which ventricular septal
defects were the most common (4/15, 26.7%) [22].
Genitourinary anomalies
The frequently associated genitourinary anomalies
in trisomy 13 fetuses, occurring unilaterally or bila-
terally, include multicystic kidneys, enlarged and
echogenic kidneys, renal cystic dysplasia, hydrone-
phrosis, ureteral obstruction, and duplication [13].
These abnormalities may be seen in approximately
one third of trisomy 13 fetuses [13]. In another study
of 28 trisomy 13 fetuses, renal anomalies were pre-
natally detected in 42.9% (12/28), of which the two
common findings were pyelectasis (8/12, 66.6%)
and renal cystic dysplasia (4/12, 33.3%) [22].
Limb anomalies
The limb defects described in trisomy 13 include
postaxial polydactyly of the hands and feet, clen-
ched or overlapping digits, prominent calcaneus,
and rocker bottom or club feet, of which postaxial
polydactyly was the most frequent in Lehman et al’s
report [13]. An epidemiologic analysis revealed
155 cases with the suspected or proved trisomy 13
cases having postaxial polydactyly and only 15 cases
having preaxial polydactyly [34]. However, in a
recent study of 28 trisomy 13 fetuses, prenatal
detection of a limb defect with postaxial polydactyly
was only documented in two cases (2/28, 7.1%)
[22]. The difficulty in prenatal sonographic detection
of limb anomalies may be strongly associated with
maternal obesity, unfavorable fetal postures, earlier
sonographic scanning, and suboptimal visualization
of fetuses.
Abdominal wall defects
Abdominal wall defects in fetuses with trisomy 13
may have omphalocele and bladder exstrophy [13].
Omphalocele may be the manifestation of a chro-
mosomal abnormality. In a study of 40 fetuses with
central type of omphalocele, trisomy 13 was the sec-
ond most frequent chromosomal abnormality (5/40,
12.5%) after trisomy 18 (29/40, 72.5%) [35]. In a
large ultrasound screening at 11–14 weeks of ges-
tation, the frequency of fetal omphaloceles with
trisomy 13 was 9.1% [36]. Although the early
diagnosis of omphalocele is often easy by prenatal
ultrasound, we should caution about the diagnosis
before the completion of the physiologic hernia-
tion in the first trimester.
Type II Markers — Soft Markers
The most common soft markers in trisomic fetuses
include a thickened nuchal fold, EIF, fetal tachy-
cardia, megacystis, intrauterine growth restriction,
echogenic bowel, single umbilical artery, shortened
femurs or humerus, renal pelvic dilation, and choroid
plexus cysts. Although these findings are seen 
in normal fetuses, they can be found in a higher
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percentage of fetal aneuploidy, and their presence
has become an important element of risk adjustment
in early pregnancy. Similar to other trisomies, soft
markers on prenatal ultrasound have been increas-
ingly applied in screening of fetal trisomy 13. The
more commonly studied soft markers for trisomy
13 include an increased fetal NT, an EIF, fetal
tachycardia, and megacystis.
Increased NT
In the first trimester, the term “fetal NT” refers to
the sonographic finding of a subcutaneous collec-
tion of fluid behind the fetal neck. Previous studies
provide evidence that increased fetal NT is signi-
ficantly associated with chromosomal abnormali-
ties [37]. Currently, the Fetal Medicine Foundation, a
registered charity in the United Kingdom, proposed
that the optimal gestational age for the measure-
ment of fetal NT is from 11 to 13+6 weeks of gesta-
tion. The corresponding fetal crown–rump length
(CRL) is between 45 mm and 84 mm. Increased NT
is defined by the vertical thickness equal to or above
the 95th centile of a reference range. The 95th centile
of NT increased linearly with fetal CRL from 2.1 mm
at a CRL of 45 mm to 2.7 mm for a CRL of 84 mm,
whereas the 99th centile did not change with CRL,
and it was approximately 3.5 mm [38]. Kagan et al
[39] reported that NT thickness was 4.5 mm or
more in approximately 60% of trisomy 13 fetuses.
In addition, maternal serum proteins including free
β-human chorionic gonadotropin (β-hCG) and
pregnancy associated plasma protein-A (PAPP-A)
are decreased in trisomy 13 fetuses [40]. Nicolaides
reported that first trimester screening by a combi-
nation of fetal NT and PAPP-A and free β-hCG can
identify approximately 90% of chromosomal aneu-
ploidies including trisomy 13, which represents a
screen positive rate of 1% [31]. After the second
trimester, nuchal cystic hygroma or nuchal edema
can be seen in approximately 20% of fetuses with
trisomy 13 [13].
EIF
An EIF is a subjective sonographic finding of an
echogenic spot over the cardiac papillary muscle
and its detection depends on a variety of factors
including resolution of the sonographic equip-
ment, the operator’s experience and the fetal pos-
ture. Approximately 3–4% of normal fetuses can be
detected with EIFs in the second trimester [41,42].
Shipp et al [43] found three times more detections
among Asian patients with EIFs compared with
white patients. In a pathologic study, Roberts and
Genest first suggested an association between aneu-
ploidy and mineralization of the papillary muscle,
which was observed in 2% of normal fetuses com-
pared with 39% of those with trisomy 13 [44].
Clinically, most trisomy 13 fetuses with EIFs also
had detection of other structural anomalies, except
for one trisomy 13 fetus who had multiple EIFs as the
only abnormal finding on prenatal ultrasound [45].
Fetal tachycardia
In first trimester studies, fetal tachycardia was
reported to be associated with trisomy 13 [46,47].
Fetal heart rate in normal pregnancy is observed to
increase from about 110 beats per minute (bpm)
at 5 weeks of gestation to 170 bpm at 9 weeks due
to cardiac structural development and then gradu-
ally to decrease to 150bpm by 14 weeks, suggestive
of functional maturation of the parasympathetic
system [48,49]. Fetal heart rate was reported to be
above the 95th centile of the normal range in 67%
of trisomy 13 fetuses and the possible explanation
of first-trimester fetal tachycardia of trisomy 13 is
associated with congenital cardiac defects such as
septal and/or valvular abnormalities [46].
Megacystis
By definition, fetal megacystis is defined by a longi-
tudinal bladder diameter of 7 mm or more at 10–14
weeks of gestation and the incidence is about 1 in
1,500 pregnancies [50]. If a longitudinal diameter
of the fetal bladder is measured as 7–15 mm during
10–14 weeks of gestation, there is a risk of approx-
imately 25% that the fetus will have a chromosomal
defect, mainly trisomies 13 or 18 [51]. Approximately
90% of fetuses with megacystis of a normal kary-
otype will spontaneously resolve without any adverse
consequence of the urinary system.
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Differential Diagnosis
The definite diagnosis of fetal trisomy 13 depends
on cytogenetic analysis. Owing to these common
structural abnormalities in fetal trisomy 13, differ-
ential diagnoses should include Meckel-Gruber
syndrome, pseudotrisomy 13 syndrome, Smith-
Lemli-Opitz syndrome, Pallister-Hall syndrome, and
hydrolethalus syndrome.
Meckel-Gruber syndrome or Meckel syndrome
(MKS, OMIM 249000)
MKS was described initially in 1822 by Meckel [52]
and redefined in 1934 by Gruber [53]. MKS is clas-
sified into three subtypes and the genetic loci have
been mapped including MKS1 (OMIM 609883)
on 17q21-q24 [54], MKS2 (OMIM 603194) on
11q13 [55], and MKS3 (OMIM 607361) on 8q21-
q22 [56]. MKS is an autosomal recessive disorder
manifesting a combination of polycystic kidneys,
anomalies of the central nervous system (typically
occipital encephalocele), hepatic ductal dysplasia
and cysts, and postaxial polydactyly [57]. Clinical
spectrums of MKS showed that cystic kidney dys-
plasia is the most common defect, whereas occipi-
tal encephalocele and polydactyly are found in
only 50% [58]. Compared with trisomy 13, occipi-
tal encephalocele but not HPE is the major brain
anomaly in MKS. In addition, oligohydramnios 
is often seen in MKS fetuses due to severe renal
dysfunction.
Pseudotrisomy 13 syndrome
(holoprosencephaly-polydactyly 
syndrome, OMIM 264480)
Patients with pseudotrisomy 13 syndrome manifest
HPE, severe facial anomalies, postaxial polydactyly,
and a normal karyotype [59]. Other congenital
defects may include cerebellar hypoplasia, ence-
phalocele, microphthalmia, cleft lip and palate, car-
diac defects, ambiguous genitalia, malformations of
the urinary and digestive system, malsegmentation
of the lungs, and adrenal hypoplasia [60]. Neither
HPE nor polydactyly is obligatory because affected
sibs did not always show these malformations [61].
Several cases provide evidence that pseudotrisomy
13 syndrome is an autosomal recessive inheritance
and carries a 25% risk of recurrence [62–65]. The
phenotypes of trisomy 13 have a considerable over-
lap with pseudotrisomy 13 and the most powerful
diagnosis in distinguishing trisomy 13 from pseu-
dotrisomy 13 relies on fetal karyotyping.
Smith-Lemli-Opitz syndrome (SLOS, 
OMIM 270400)
SLOS is a metabolic syndrome of multiple congenital
malformations characterized by psychomotor retar-
dation, growth restriction, cleft palate, postaxial
polydactyly, and rare craniofacial abnormalities
including microcephaly, micrognathia, and HPE.
The causative factor is deficiency of 7-dehydrocho-
lesterol reductase (DHCR7) resulting from muta-
tions in the DHCR7 gene mapping to 11q12-q13
[66]. The reductase is the final enzyme of the cho-
lesterol biosynthetic pathway. Prenatal diagnosis
of SLOS can be done by biochemical analysis of 
7-dehydrocholesterol levels in amniotic fluid or
chorionic villi and mutation analysis of the DHCR7
gene [67,68]. Since recently, steroid measurements
in maternal urine are supposed to be a reliable basis
for prenatal diagnosis [69].
Pallister-Hall syndrome (PHS, OMIM 146510)
PHS is defined by postaxial polydactyly, hypotha-
lamic hamartoma, abnormal lung lobations, renal
agenesis or dysplasia, epiglottic or laryngeal clefts,
congenital heart defects, and intrauterine growth
restriction. The syndrome is caused by frameshift,
nonsense, and splicing mutations in the zinc finger
transcription factor gene, GLI3, mapping to 7p13
[70]. The specific finding of hypothalamic hamar-
toma in PHS is different from HPE in trisomy 13 and
magnetic resonance imaging is the most valuable
diagnostic tool [71].
Hydrolethalus syndrome (HYLS, OMIM
236680)
Hydrolethalus syndrome, discovered in Finland,
was characterized by midbrain anomalies with
severe hydrocephalus, micropolygyria, facial clefts,
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micrognathia, and polydactyly [72]. It is caused by
mutations in the HYLS1 gene on 11q24.2 (OMIM
610693) [73]. In the brain, the foramen magnum
is keyhole shaped and the hydrocephalus is exter-
nal because the ventricles are open to the sub-
arachnoid space. Clinically, polyhydramnios often
occurs during the pregnancy and the characteris-
tics of polydactyly are postaxiality in the hands and
preaxiality in the feet.
Conclusion
In the modern era, the use of prenatal ultrasound
in aneuploidy risk estimation has improved clinical
obstetric practice. Clinically, triple maternal serum
screening with α-fetoprotein, free β-hCG, and
unconjugated estriol in the second trimester is not
useful in detecting trisomy 13 fetuses. Statistically,
sonographic findings of structural defects can iden-
tify more than 90% of trisomy 13 fetuses through-
out the gestation. Despite the fact that sonographic
features of trisomy 13 may overlap with those of
other syndromes, fetuses with brain defects, midline
facial defects, cardiac anomalies, genitourinary ano-
malies, limb anomalies, and abdominal wall defects
are strongly suggestive of trisomy 13 and further
fetal karyotyping is warranted. In the first trimester
screening for trisomy 13 fetuses, the addition of
sonographic soft markers including increased fetal
NT and absent or hypoplastic nasal bone demon-
strably benefits pregnant women in obtaining more
personalized risk assessment. Due to the lethal syn-
drome, prenatal ultrasound has been demonstrated to
be a valuable tool in detecting a variety of congenital
structural malformations of trisomy 13 throughout
the gestation.
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